Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TC-E202 TCR-T therapy in HPV16+ cervical cancer
NCT05357027Phase 2Terminated
- Sponsor
- TCRCure Biotech
- Start
- Aug 2022
- Primary completion
- Jan 2026
- Modality
- Gene Editing, Gene Silencing, Cell Therapies
- Countries
- 1
01
Overview
A Phase 2 trial of TC-E202 in cervical carcinoma, sponsored by TCRCure Biotech. Started Aug 2022; status: terminated.
02
Drugs
TC-E202
03
Conditions
cervical carcinoma
Beyond the preview
Go deeper on NCT05357027.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05357027.